Cognition Therapeutics Inc. CGTX
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026
Cognition Therapeutics Inc. (CGTX) is a healthcare company listed in the US with a market value of about $65M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -123%.
About Cognition Therapeutics
Cognition Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. It was profitable in 0 of the last 6 years in our data. Its share count rose by 208% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net income | -$23M | -$34M | -$26M | -$21M | -$12M | -$8M |
| Free cash flow | — | -$28M | -$16M | -$19M | -$4M | -$3M |
| EPS (diluted) | $-0.32 | $-0.86 | $-0.86 | $-0.91 | $-3.13 | $-23.76 |
| Net margin | — | — | — | — | — | — |
| ROIC | -109.1% | -221.1% | -159.2% | -83.7% | -44.1% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Cognition Therapeutics pay a dividend?
Not currently.
Is Cognition Therapeutics a good stock to buy?
We do not give buy or sell advice. Cognition Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.